Plaque Psoriasis

Mona Shahriari, MD, discusses the evolving role of nonsteroidal topical options the management of plaque psoriasis.

These multicenter, retrospective data highlight the use of guselkumab after discontinuing ustekinumab treatment up to 156 weeks of use.

A new study found a negative correlation between salivary rates and disease severity for patients with psoriasis.

A new study found patients with psoriasis and depression have increased levels of C-reaction proteins and the erythrocyte sedimentation rate.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

These findings highlight potential drawbacks of treating psoriasis with phototherapy versus anti-TNFα therapy, though additional research is needed.

This retrospective, systematic review highlighted the lack of studies specifically addressing the needs of patients with inverse psoriasis.

These data on genetic correlations allow for new genetic evidence connecting psoriasis and patients’ socioeconomic status.

These data highlight the effects of psoriasis on the mental health of adolescents in Denmark.

In this analysis of independent risk factors for developing PsA from psoriasis, the use of MRI to detect such factors was noted as helpful for investigators.

These data highlighted patient-reported and clinical outcomes among those with psoriasis, with data drawn retrospectively from Germany, Poland, Czech Republic, Japan, and Canada.

Biologic therapy for psoriasis showed no significant impact on cardiovascular risk factors over one year in a retrospective study from Australia.

These results may support clinical decision-making for psoriasis and nail psoriasis management and may allow future real-world studies to further understand the nature of this skin disease.

A study showed tildrakizumab treated difficult-to-treat psoriasis areas in patients who failed anti-IL17 treatment.

The tool’s development for scoring severity among complex nail psoriasis cases and monitoring response to treatment may allow for improved outcomes among patients.

These data suggest that a multidisciplinary clinic approach results in several benefits including reduced risk of cardiovascular events among those with psoriasis.

These data highlight the elements known to impact patient-reported outcomes among those with psoriasis and successful clinician-reported outcomes following biologic use.

A new study found specific sociodemographic factors were linked to 76.4% lower odds of adhering to topical therapy for psoriasis.

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab.

These data allow for a basis for additional research and possible interventions to address psoriasis patients’ demodicosis risk.

Experts conclude the series discussing how to approach switching psoriasis treatments.

Experts discuss package warnings associated with bimekizumab and how they inform patients of them.

Experts discuss bimekizumab for the treatment of psoriasis highlighting is efficacy over other treatments.

Dermatologists Drs Tina Bhutani and Scott Boswell and a patient share resources and tools available to cope with generalized pustular psoriasis (GPP).